Histology independent cancer drugs: the drug makers’ responsibility
Cooper and colleagues raise important challenges for health technology assessment (HTA) organisations in evaluating the benefits, risks, and cost effectiveness of drugs that target a genetic mutation…
Read Original Article: Histology independent cancer drugs: the drug makers’ responsibility »
